Correlation between circulating miR-135a level and antioxidant function of HDL
Author:
Affiliation:

1.Department of Cardiology, Zhongnan Hospital of Wuhan University & Institute of Myocardial Injury and Repair of Wuhan University, Wuhan, Hubei 430071, China;2.School of Basic Medical Sciences, Wuhan University & Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, Hubei 430071, China)

Clc Number:

R5

  • Article
  • | |
  • Metrics
  • |
  • Reference [20]
  • | | | |
  • Comments
    Abstract:

    Aim To study the correlation between the antioxidantion of plasma high density lipoprotein (HDL) and circulating microRNA (miRNA). Methods Scavenger receptor group B type Ⅰ deficient (SR-BⅠ-/-) mice as dysfunctional HDL model mice were used to explore the changes of specific miRNA spectrum. From September 2020 to May 1,0 patients with coronary artery disease (CAD) were enrolled in the Department of Cardiology, Zhongnan Hospital of Wuhan University, non-CAD patients in the same period as control group, both groups with HDL cholesterol (HDLC) higher than 1.04 mmol/L. Results Compared with wild-type mice, the plasma miR-135a in SR-BⅠ-/- mice decreased significantly. Plasma paraoxonase 1 (PON-1) activity decreased in CAD patients, PON-1 activity in control group was positively correlated with HDLC level, but not in CAD group. The plasma miR-135a level in CAD patients also decreased, and was positively correlated with PON-1 activity. In CAD group, the level of plasma miR-17 decreased significantly, and the levels of miR-223 and miR-760 increased significantly, but there was no correlation with HDLC level or plasma PON-1 activity. Conclusion The level of plasma miR-135a decreased significantly in CAD patients with high HDLC, and was positively correlated with PON-1 activity, which may be related to the antioxidant function of HDL.

    Reference
    [1] TABAS I, GARCA-CARDEA G, OWENS G K.Recent insights into the cellular biology of atherosclerosis.J Cell Biol, 5,9(1):13-22.
    [2] FISHER E A, FEIG J E, HEWING B, et al.High-density lipoprotein function, dysfunction, and reverse cholesterol transport.Arterioscler Thromb Vasc Biol, 2,2(12):2813-2820.
    [3] Gangwar S R, RAJAGOPALAN S, Natarajan R, et al.Noncoding RNAs in cardiovascular disease:pathological relevance and emerging role as biomarkers and therapeutics.Am J Hypertens, 8,1(2):150-165.
    [4] VELLE-FORBORD T, EIDLAUG M, DEBIK J, et al.Circulating microRNAs as predictive biomarkers of myocardial infarction:evidence from the HUNT study.Atherosclerosis, 9,9:1-7.
    [5] VICKERS K C, PALMISANO B T, SHOUCRI B M, et al.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.Nat Cell Biol, 1,3(4):423-433.
    [6] GANJALI S, MOMTAZI A A, BANACH M, et al.HDL abnormalities in familial hypercholesterolemia:focus on biological functions.Prog Lipid Res, 7,7:16-26.
    [7] TABET F, VICKERS K C, CUESTA T L, et al.HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.Nat Commun, 4,5:3292.
    [8] ZANONI P, KHETARPAL S A, LARACH D B, et al.Rare variant in scavenger receptor BⅠ raises HDL cholesterol and increases risk of coronary heart disease.Science, 6,1(6278):1166-1171.
    [9] CAO J, XU Y, LI F, et al.Protein markers of dysfunctional HDL in scavenger receptor class B type Ⅰ deficient mice.J Transl Med, 8,6(1):155.
    [10] BAN E, CHAE D K, YOO Y S, et al.An improvement of miRNA extraction efficiency in human plasma.Anal Bioanal Chem, 7,9(27):6397-6404.
    [11] KNUUTI J, WIJNS W, SARASTE A, et al.2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.Eur Heart J, 0,1(3):407-477.
    [12] GOTTO A M, BRINTON E A.Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:a working group report and update.J Am Coll Cardiol, 4,3(5):717-724.
    [13] SIDDIQI H K, RADER D.HDL cholesterol and cardiovascular disease:rethinking our approach.Curr Opin Cardiol, 5,0(5):536-542.
    [14] FERRI N, CORSINI A, SIRTORI C R, et al.Present therapeutic role of cholesteryl ester transfer protein inhibitors.Pharmacol Res, 8,8:29-41.
    [15] Linton F M, TAO H, Linton E F, et al.SR-BⅠ:a multifunctional receptor in cholesterol homeostasis and atherosclerosis.Trends Endocrinol Metab, 7,8(6):461-472.
    [16] MUTHURAMU I, AMIN R, ABOUMSALLEM J P, et al.Hepatocyte-specific SR-BⅠ gene transfer corrects cardiac dysfunction in scarb1-deficient mice and improves pressure overload-induced cardiomyopathy.Arterioscler Thromb Vasc Biol, 8,8(9):2028-2040.
    [17] 杜芬, 喻红.清道夫受体BⅠ与动脉粥样硬化.中国动脉硬化杂志, 8,6(11):1177-1183.
    [18] WANG Q, WU J, ZENG Y, et al.Pyroptosis:a pro-inflammatory type of cell death in cardiovascular disease.Clin Chim Acta, 0,0:62-72.
    [19] SPINNER C A, LAZAREVIC V.Transcriptional regulation of adaptive and innate lymphoid lineage specification.Immunol Rev, 1,0(1):65-81.
    [20] DENG Y Q, YANG Y Q, WANG S B, et al.Intranasal administration of lentiviral miR-135a regulates mast cell and allergen-induced inflammation by targeting GATA-3.PLoS One, 5,0(9):e0139322.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

GE Haijing, Lü Xintong, HE Tao, YU Hong, LU Zhibing, DU Fen. Correlation between circulating miR-135a level and antioxidant function of HDL[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2022,30(3):198-204.

Copy
Share
Article Metrics
  • Abstract:965
  • PDF: 876
  • HTML: 0
  • Cited by: 0
History
  • Received:July 29,2021
  • Revised:October 21,2021
  • Online: January 14,2022
Article QR Code